missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ eIF4A1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5115167
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total EIF4A1.
eIF4A2 is a 407 amino acid ATP-dependent RNA helicase belonging to the DEAD box helicase family. It contains one helicase ATP-binding domain and a helicase C-terminal domain. eIF4A2, a subunit of the eIF4F complex, acts as a protein-synthesis initiation factor and thus plays an important role in the binding of mRNA to the 43S pre-initiation complex of ribosomes. Human eIF4A2 interacts with the NS5B protein of Hepatitis C virus (HCV) and facilitates the genomic RNA synthesis of NS5B protein by unwinding the secondary structure of the HCV genome. It is ubiquitously expressed in most of normal tissues, but in variable amounts.
Specifications
| eIF4A1 | |
| Polyclonal | |
| Unconjugated | |
| EIF4A1 | |
| ATP-dependent RNA helicase eIF4A-1; BM-010; DDX2A; Eif4; EIF4A; EIF-4A; Eif4a1; eIF-4A-I; eIF4A-I; eukaryotic initiation factor 4AI; Eukaryotic initiation factor 4A-I; eukaryotic translation initiation factor 4A, isoform 1; eukaryotic translation initiation factor 4A1; initiation factor eIF-4A long form; QtsA-12280; unnamed protein product | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 13681, 1973, 287436 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (PFA fixed), Western Blot | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide | |
| P60842, P60843 | |
| EIF4A1 | |
| A synthesized peptide derived from human EIF4A1(Accession P60842), corresponding to amino acid residues V22-V72. | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?